Source comparison
CJC-1295 No DAC for Men: Comparison Analysis
Half-Life ~30 minutes 6–8 days 2.5–3 hours (subcutaneous) No DAC requires multiple daily doses but preserves pulsatile secretion. Critical for long-term receptor sensitivity Dosing Frequency 1–3× daily 1–2× weekly Daily (sometimes twice daily) No DAC aligns be
This comparison does not assign a generated winner or score.
- Half-Life
- ~30 minutes
- 6–8 days
- 2.5–3 hours (subcutaneous)
- No DAC requires multiple daily doses but preserves pulsatile secretion. Critical for long-term receptor sensitivity
- Dosing Frequency
- 1–3× daily
- 1–2× weekly
- Daily (sometimes twice daily)
- No DAC aligns best with physiological GH rhythm; DAC version risks receptor downregulation after 2–3 weeks
- Mechanism
- Stimulates endogenous GH release via GHRH receptor
- Stimulates endogenous GH release (sustained)
- Exogenous GH replacement
- Only no DAC and rhGH avoid negative feedback suppression of endogenous production
- IGF-1 Elevation
- 1.5–2.0× baseline (pulsatile)
- 1.8–2.5× baseline (sustained)
- 2.5–4.0× baseline (dose-dependent)
- rhGH produces highest IGF-1 but at the cost of endogenous shutdown; no DAC offers middle ground
- Receptor Desensitization Risk
- Low (short half-life)
- High (continuous activation)
- Moderate (depends on dosing pattern)
- No DAC is the only GHRH analogue suitable for protocols exceeding 8–12 weeks without planned off-cycles
- Cost Per 30-Day Protocol
- $120–180 (100 mcg 3× daily)
- $80–120 (single weekly dose)
- $600–1,200 (2–4 IU daily)
- DAC appears cheaper per dose but loses efficacy over time; no DAC maintains consistent response across months